Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma

NCT02617485 is registered in ClinicalTrials.gov with Mabion SA as lead sponsor.

NCT NCT02617485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02617485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma
Lead sponsor
Mabion SA
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
January 31, 2018
Enrollment
143 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma